Table 2.
Concomitant Diseases And Medication Use At Baseline In The Treated Set
| Concomitant diseases | Number (%) of patientsa |
|---|---|
| Allergic disease | 153 (2.1) |
| Cardiac | 3162 (42.5) |
| Gastrointestinal/hepatobiliary | 914 (12.3) |
| Metabolic/endocrine | 1799 (24.2) |
| Musculoskeletal/dermatologic | 488 (6.6) |
| Neurologic | 307 (4.1) |
| Pulmonary (except COPD) | 439 (5.9) |
| Psychiatric | 274 (3.7) |
| Renal/urogenital | 367 (4.9) |
| Vascular | 2174 (29.2) |
| Other | 424 (5.7) |
| COPD therapies taken 6 months prior to study start | |
| ICS monotherapy | 326 (4.4) |
| LABA | 1100 (14.8) |
| LAMA | 1999 (26.9) |
| SABA | 1056 (14.2) |
| SAMA | 513 (6.9) |
| SAMA+SABA in fixed-dose combination | 1071 (14.4) |
| LABA+ICS | 859 (11.5) |
| LAMA+LABA in fixed-dose combination | 50 (0.7) |
| Systemic corticosteroid | 45 (0.6) |
| Theophylline | 719 (9.7) |
| Roflumilast | 36 (0.5) |
| Other | 192 (2.6) |
Notes: a“Multiple answers possible”, meaning that patients might have more than one concomitant disease.
Abbreviations: ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; SABA, short-acting β2-agonist; SAMA, short-acting muscarinic antagonist.